Stocks Health care NMRA
NASDAQ · Health careNeumora Therapeutics, Inc. (NMRA)
It posted a net loss of $212.7M. At June 30, 2026 it held $116.8M in cash against $52.9M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 14, 2026.
Key facts about Neumora Therapeutics, Inc.
- Net worth
- Neumora Therapeutics, Inc. has a market value (market cap) of $87.7M at the latest share price, and shareholders' equity of $44.5M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Cash flow
- In fiscal 2025 operations used $206.4M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 14, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Neumora Therapeutics, Inc.'s next report was expected around November 5, 2026 and is not on file with the SEC yet.
What Neumora Therapeutics, Inc. does
Neumora Therapeutics, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker NMRA.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$236.9M | -$1.45 | n/a |
| 2024 | n/a | -$243.8M | -$1.53 | n/a |
| 2023 | n/a | -$235.9M | -$3.63 | -$163.4M |
| 2023 | n/a | -$130.9M | -$4.81 | -$115.4M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Neumora Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- October 30, 2026
- August 14, 2026
- August 14, 2026
- July 27, 2026Other event 8-K
- June 15, 2026
- May 29, 2026
- May 15, 2026Passive stake changed SCHEDULE 13G/A
- May 7, 2026
- May 7, 2026
- May 4, 2026Passive stake changed SCHEDULE 13G/A
Insider trades
What the people running Neumora Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $701.6K worth of shares in the last 90 days and bought none on the open market.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| August 21, 2026 | Aurora Daljit SinghSee Remarks | Exercised options | 20,553 | $14.8K |
| August 21, 2026 | Aurora Daljit SinghSee Remarks | Sold | 20,553 | $32.8K |
| August 21, 2026 | Aurora Daljit SinghSee Remarks | Exercised optionsindirect | 21,055 | $15.2K |
| August 21, 2026 | Aurora Daljit SinghSee Remarks | Soldindirect | 21,055 | $33.6K |
| August 20, 2026 | Aurora Daljit SinghSee Remarks | Exercised options | 67,741 | $48.8K |
| August 20, 2026 | Aurora Daljit SinghSee Remarks | Sold | 67,741 | $102.6K |
| August 20, 2026 | Aurora Daljit SinghSee Remarks | Exercised optionsindirect | 21,685 | $15.6K |
| August 20, 2026 | Aurora Daljit SinghSee Remarks | Exercised optionsindirect | 45,026 | $32.4K |
Who owns NMRA
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Kristina Burow13D, may seek influence with 17 related filers | 18.7% | April 1, 2026 |
| Paul L Berns13G, passive | 5.1% | February 13, 2025 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 113 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Siren, L.L.C. | 8,497,822 | 0 |
| BlackRock, Inc. | 7,791,869 | +5,737,553 |
| Softbank Group Corp. | 6,090,301 | 0 |
| Vanguard Capital Management LLC | 4,669,585 | +777,692 |
| MIC Capital Management UK LLP | 4,460,700 | 0 |
| Fmr LLC | 3,498,869 | +211 |
| WELLCOME TRUST LTD (THE) as trustee of the WELLCOME TRUST | 3,309,123 | 0 |
| Geode Capital Management, LLC | 2,607,289 | +1,520,424 |
| ICONIQ Capital, LLC | 2,559,090 | 0 |
| Two Sigma Investments, LP | 2,244,829 | +208,137 |
| Orbimed Advisors LLC | 2,139,882 | new |
| Lunate Capital Ltd | 2,124,143 | 0 |
| Boxer Capital Management, LLC | 2,000,000 | new |
| Johnson & Johnson | 1,849,445 | 0 |
| State Street Corp | 1,582,119 | +1,183,400 |
| Tudor Investment Corp ET AL | 1,356,147 | +584,729 |
| Ikarian Capital, LLC | 1,278,408 | 0 |
| Renaissance Technologies LLC | 1,262,304 | -126,694 |
| Affinity Asset Advisors, LLC | 1,070,651 | new |
| Marshall Wace, Llp | 904,458 | -290,852 |
Insiders
4 insiders reported holding 7,522,752 shares in total, about $3.5M at the last price.
| Holder | Shares |
|---|---|
| Berns Paul LSee Remarks, Director | 7,395,185 |
| Pinto JoshuaPresident | 57,783 |
| Aurora Daljit SinghSee Remarks | 48,750 |
| Milligan Michael LeeSee Remarks | 21,034 |
Questions about NMRA
What does Neumora Therapeutics, Inc. do?
Neumora Therapeutics, Inc. is a company in the Health care sector, listed on NASDAQ as NMRA. Its shares trade on NASDAQ under the ticker NMRA.
What is Neumora Therapeutics, Inc.'s net worth?
Neumora Therapeutics, Inc. has a market value (market cap) of $87.7M at the latest share price, and shareholders' equity of $44.5M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Neumora Therapeutics, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $212.7M.
When did Neumora Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 14, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the stock exchange listing notice from October 30, 2026.
When is Neumora Therapeutics, Inc.'s next earnings report?
Neumora Therapeutics, Inc.'s next report was expected around November 5, 2026 and is not on file with the SEC yet.
Similar companies
Compare NMRA with
Follow NMRA
Get an email when Neumora Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Neumora Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.